Evidence map›Paper›PMID 36188145›Full record

ReviewWorld journal of diabetes2022

COVID-19 associated diabetes mellitus: A review.

Ajay M Gavkare, Neeta Nanaware, Abhijit S Rayate, Sachin Mumbre, Basavraj S Nagoba

Abstract readReview
In one paragraph

Review in World journal of diabetes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Diabetic peripheral arterial disease in COVID-19 pandemic.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2024
    Review
  6. COVID-19, the escalation of diabetes mellitus and the repercussions on tuberculosis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023
    Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ajay M GavkarePhysiology, Maharashtra Institute of Medical Sciences & Research (Medical College), Latur 413531, Maharashtra, India.
Neeta NanawarePhysiology, Vilasrao Deshmukh Government Medical College, Latur 413512, Maharashtra, India.
Abhijit S RayateSurgery, Maharashtra Institute of Medical Sciences & Research (Medical College), Latur 413531, Maharashtra, India.
Sachin MumbreCommunity Medicine, Ashwini Rural Medical College, Solapur 413006, Maharashtra, India.
Basavraj S NagobaMicrobiology, Maharashtra Institute of Medical Sciences & Research (Medical College), Latur 413531, Maharashtra, India. dr_bsnagoba@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A significantly higher rate of new-onset diabetes in many coronavirus disease 2019 (COVID-19) patients is a frequently observed phenomenon. The resultant hyperglycemia is known to influence the clinical outcome, thereby increasing the cost of treatment and stay in hospital. This will also affect the post-hospitalization recuperation. It has been observed that new-onset diabetes in COVID-19 patients is associated with considerable increase in morbidity and may be associated with increased mortality in some cases. This mini-review focuses on the possible causes to understand how COVID-19-related diabetes develops, various associated risk factors, and possible mechanism to understand the natural history of the disease process, clinical outcome, associated morbidities and various treatment options in the mana-gement of post COVID-19 diabetes. A literature search was performed in PubMed and other online database using appropriate keywords. A total of 80 articles were found, among which, 53 of the most relevant were evaluated/ analyzed and relevant data were included. The studies show that patients who have had severe acute respiratory syndrome coronavirus 2 infection leading to development of COVID-19 may manifest not only with new-onset diabetes but also worsening of pre-existing diabetes. Cytopathic effect and autoimmune destruction of insulin-secreting pancreatic beta cells, cytokine storm during the active phase of infection causing impaired insulin secretion and resistance, drug-induced hyperglycemia, undetected pre-existing hyperglycemia/diabetic condition, and stress-induced impairment of glucose metabolism are some of the possible potential mechanisms of COVID-19-associated new-onset diabetes mellitus. Many studies published in recent times have found a significantly higher rate of new-onset diabetes mellitus in many COVID-19 patients. Whether it is an inflammatory or immune-mediated response, direct effect of virus or combination of these is unclear. The resultant hyperglycemia is known to influence the clinical outcome and has been associated with considerable increase in morbidity and increased mortality in some cases.

Indexed as

Coronavirus disease 2019Coronavirus disease 2019 associated diabetesCoronavirus disease 2019 related diabetesHyperglycemia in coronavirus disease 2019 patientsNew-onset diabetesPost-coronavirus disease 2019 diabetes

Identifiers

PMID36188145
PMCPMC9521440

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.